GLP‑1 enforcement expands
FDA and industry enforcement is shifting toward cracking down on compounded GLP‑1 weight‑loss products and questionable telehealth promotion, with regulators and brand owners actively pursuing takedowns and legal action. Because alternate access channels can muddy provenance, these enforcement moves matter for how adverse events are attributed and investigated when product source, formulation or dispensing route is uncertain. (pharmacytimes.com)
The Food and Drug Administration sent 30 warning letters on March 3, 2026 to telehealth companies over online claims about compounded glucagon-like peptide-1 drugs, and the agency said the main problems were ads that implied the products were the same as approved medicines and ads that hid who actually made them. (fda.gov) That is a sharp turn from the last two years, when the boom in weight-loss demand let online clinics, med spas, and compounders sell versions of semaglutide and tirzepatide through websites that often looked like ordinary brand-name checkout pages. (fda.gov) (pharmacytimes.com) Compounding is the pharmacy version of custom tailoring: a pharmacist changes a drug for a specific patient, usually because a dose, ingredient, or form is not otherwise available. The Food and Drug Administration says compounded drugs are not reviewed by the agency for safety, effectiveness, or quality before sale. (fda.gov) That exception grew during shortages. The Food and Drug Administration said its enforcement discretion for state-licensed pharmacy compounding of tirzepatide ended in March 2025, and its enforcement discretion for state-licensed pharmacy compounding of semaglutide ended in April 2025 after court rulings and shortage updates. (fda.gov) Once those shortage windows closed, the legal ground shifted from “temporary workaround” to “why is this still being mass-marketed.” The Food and Drug Administration said in its March 2026 letters that compounders should not use compounding to bypass the normal approval system by selling at scale. (fda.gov) The agency is also pointing to concrete safety problems, not just paperwork. The Food and Drug Administration says it has received complaints about compounded glucagon-like peptide-1 injections arriving warm, and it has warned that refrigeration failures can affect drug quality. (fda.gov) Dosing has been another weak spot. The Food and Drug Administration said in a 2024 alert that some patients were hospitalized after overdoses tied to compounded semaglutide, with errors linked to patients measuring doses and to health professionals miscalculating them. (fda.gov) The supply chain is part of the crackdown too. The Food and Drug Administration says it created import alert 66-80 to help block glucagon-like peptide-1 active ingredients with potential quality concerns from entering the United States supply chain. (fda.gov) Drugmakers are pushing in parallel. Novo Nordisk said on August 5, 2025 that it had filed more than 130 lawsuits across 40 states over what it called unsafe, non-Food and Drug Administration-approved compounded semaglutide, and it said those cases had already produced 44 permanent injunctions. (prnewswire.com) That pressure is changing business models in public. On March 9, 2026, Novo Nordisk said it would expand United States access to approved semaglutide medicines through Hims & Hers, and Hims & Hers said the partnership would shift its weight-loss business toward a broader menu of Food and Drug Administration-approved glucagon-like peptide-1 products. (novonordisk.com) (investors.hims.com) The hard part for regulators is that a bad reaction is easier to investigate when the box, label, lot number, and manufacturer are clear. When a patient gets a drug through a telehealth brand, a compounding pharmacy, a shipped cold pack, and a customized vial, every extra handoff makes it harder to know whether the problem came from the molecule, the dose, the storage, or the source. (fda.gov 1) (fda.gov 2)
